GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » Change In Payables And Accrued Expense

Tourmaline Bio (Tourmaline Bio) Change In Payables And Accrued Expense : $-1.87 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Tourmaline Bio Change In Payables And Accrued Expense?

Tourmaline Bio's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was $-0.20 Mil. It means Tourmaline Bio's Accounts Payable & Accrued Expense declined by $0.20 Mil from Dec. 2023 to Mar. 2024 .

Tourmaline Bio's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $2.28 Mil. It means Tourmaline Bio's Accounts Payable & Accrued Expense increased by $2.28 Mil from Dec. 2022 to Dec. 2023 .

Tourmaline Bio Change In Payables And Accrued Expense Historical Data

The historical data trend for Tourmaline Bio's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tourmaline Bio Change In Payables And Accrued Expense Chart

Tourmaline Bio Annual Data
Trend Dec21 Dec22 Dec23
Change In Payables And Accrued Expense
- 0.96 2.28

Tourmaline Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only 3.96 -1.98 -4.97 5.27 -0.20

Tourmaline Bio Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tourmaline Bio Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Tourmaline Bio's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Tourmaline Bio (Tourmaline Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » Change In Payables And Accrued Expense
Comparable Companies
CYTK NUVL KRYS CRSP INSM FOLD BPMC IMGN AXSM ACAD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
27 West 24th Street, Suite 702, New York, NY, USA, 10010
Website
https://www.tourmalinebio.com
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.